
MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending. If that holds up, it is the most concrete answer yet to a question the sector has been…
No discussion yet. Be the first to share your thoughts!